Condition
Post-polycythemia Vera Myelofibrosis (Post-PV MF)
Total Trials
4
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Recruiting2
Active Not Recruiting1
Terminated1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07340138Phase 1Recruiting
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
NCT03441113Phase 2Active Not Recruiting
Extended Access of Momelotinib in Adults With Myelofibrosis
NCT07362225Recruiting
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
NCT03935555Phase 1Terminated
Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
Showing all 4 trials